Differentiating between UCTD and early-stage SLE: from definitions to clinical approachShow others and affiliations
2022 (English)In: Nature Reviews Rheumatology, ISSN 1759-4790, E-ISSN 1759-4804, Vol. 18, p. 9-21Article, review/survey (Refereed) Published
Abstract [en]
Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous clinical manifestations that can potentially affect every organ and system. SLE is usually identified on the basis of clinical or serological manifestations; however, some individuals can present with signs and symptoms that are consistent with SLE but are not sufficient for a definite diagnosis. Disease in these individuals can either progress over time to definite SLE or remain stable, in which case their disease is often described as intermediate, possible or probable SLE. Alternatively, such individuals might have undifferentiated connective tissue disease (UCTD). Being able to differentiate between those with stable UCTD and those with SLE at an early stage is important to avoid irreversible target-organ damage from occurring. This Review provides insight into existing and evolving perceptions of the early stages of SLE, including clinical and mechanistic considerations, as well as potential paths towards early identification and intervention. Further research into the earliest phases of SLE will be important for the development of targeted diagnostic approaches and biomarkers for the identification of individuals with early disease who are likely to progress to definite SLE.
Place, publisher, year, edition, pages
Nature Publishing Group, 2022. Vol. 18, p. 9-21
National Category
Rheumatology and Autoimmunity
Identifiers
URN: urn:nbn:se:oru:diva-95423DOI: 10.1038/s41584-021-00710-2ISI: 000717407100001PubMedID: 34764455Scopus ID: 2-s2.0-85118857983OAI: oai:DiVA.org:oru-95423DiVA, id: diva2:1611388
2021-11-152021-11-152023-12-08Bibliographically approved